Please ensure Javascript is enabled for purposes of website accessibility
First Coronavirus Vaccine Tests Begin. Public Availability Many Months Away.
gvw_ap_news
By Associated Press
Published 4 years ago on
March 16, 2020

Share

SEATTLE — U.S. researchers gave the first shots in a first test of an experimental coronavirus vaccine Monday, leading off a worldwide hunt for protection even as the pandemic surges.
With careful jabs in the arms of four healthy volunteers, scientists at the Kaiser Permanente Washington Research Institute in Seattle began an anxiously awaited first-stage study of a potential COVID-19 vaccine developed in record time after the new virus exploded out of China and fanned out across the globe.

“We’re team coronavirus now. Everyone wants to do what they can in this emergency.” — Kaiser Permanente study leader Dr. Lisa Jackson
“We’re team coronavirus now,” Kaiser Permanente study leader Dr. Lisa Jackson said on the eve of the experiment. “Everyone wants to do what they can in this emergency.”
The Associated Press observed as the study’s first participant, an operations manager at a small tech company, received the injection in an exam room.
“We all feel so helpless. This is an amazing opportunity for me to do something,” Jennifer Haller, 43, of Seattle said before getting vaccinated. Her two teenagers “think it’s cool” that she’s taking part in the study.
After the injection, she left the exam room with a big smile: “I’m feeling great.”
Three others were next in line for a test that will ultimately give 45 volunteers two doses, a month apart.
Neal Browning, 46, of Bothell, Washington, is a Microsoft network engineer who says his young daughters are proud he volunteered.

There’s No Chance Participants Could Get Infected

“Every parent wants their children to look up to them,” he said. But he’s told them not to brag to their friends. “It’s other people, too. It’s not just Dad out there.”
Monday’s milestone marked just the beginning of a series of studies in people needed to prove whether the shots are safe and could work. Even if the research goes well, a vaccine would not be available for widespread use for 12 to 18 months, said Dr. Anthony Fauci of the U.S. National Institutes of Health.
Still, finding a vaccine “is an urgent public health priority,” Fauci said in a statement Monday. The new study “is an important first step toward achieving that goal.”
This vaccine candidate, code-named mRNA-1273, was developed by the NIH and Massachusetts-based biotechnology company Moderna Inc. There’s no chance participants could get infected because the shots do not contain the coronavirus itself.
It’s not the only potential vaccine in the pipeline. Dozens of research groups around the world are racing to create a vaccine against COVID-19. Another candidate, made by Inovio Pharmaceuticals, is expected to begin its own safety study next month in the U.S., China and South Korea.
The Seattle experiment got underway days after the World Health Organization declared the new virus outbreak a pandemic because of its rapid global spread, which has infected more than 169,000 people and killed more than 6,500.

Photo of the first shot given in the first-stage safety study clinical trial of a potential vaccine for COVID-19
A syringe containing the first shot given in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, rests on a table, Monday, March 16, 2020, at the Kaiser Permanente Washington Health Research Institute in Seattle. (AP Photo/Ted S. Warren)

Working Around-The-Clock Readying the Research

COVID-19 has upended the world’s social and economic fabric since China first identified the virus in January, with broad regions shuttering schools and businesses, restricting travel, canceling entertainment and sporting events, and encouraging people to stay away from each other.
Starting what scientists call a first-in-humans study is a momentous occasion for scientists, but Jackson described her team’s mood as “subdued.” They’ve been working around-the-clock readying the research in a part of the U.S. struck early and hard by the virus.
Still, “going from not even knowing that this virus was out there … to have any vaccine” in testing in about two months is unprecedented, Jackson told the AP.
Some of the study’s carefully chosen healthy volunteers, ages 18 to 55, will get higher dosages than others to test how strong the inoculations should be. Scientists will check for any side effects and draw blood samples to test if the vaccine is revving up the immune system, looking for encouraging clues like the NIH earlier found in vaccinated mice.
“We don’t know whether this vaccine will induce an immune response or whether it will be safe. That’s why we’re doing a trial,” Jackson stressed. “It’s not at the stage where it would be possible or prudent to give it to the general population.”
Most of the vaccine research under way globally targets a protein aptly named “spike” that studs the surface of the new coronavirus and lets it invade human cells. Block that protein and people cannot get infected.

The Body Will Become a Mini-Factory, Producing Some Harmless Spike Protein

Researchers at the NIH copied the section of the virus’ genetic code that contains the instructions for cells to create the spike protein. Moderna encased that “messenger RNA” into a vaccine.

The idea: The body will become a mini-factory, producing some harmless spike protein. When the immune system spots the foreign protein, it will make antibodies to attack — and be primed to react quickly if the person later encounters the real virus.
The idea: The body will become a mini-factory, producing some harmless spike protein. When the immune system spots the foreign protein, it will make antibodies to attack — and be primed to react quickly if the person later encounters the real virus.
That’s a much faster way of producing a vaccine than the traditional approach of growing virus in the lab and preparing shots from either killed or weakened versions of it.
But because vaccines are given to millions of healthy people, it takes time to test them in large enough numbers to spot an uncommon side effect, cautioned Dr. Nelson Michael of the Walter Reed Army Institute of Research, which is developing a different vaccine candidate.
“The science can go very quickly but, first, do no harm, right?” he told reporters last week.
The Seattle research institute is part of a government network that tests all kinds of vaccines and was chosen for the coronavirus vaccine study before COVID-19 began spreading widely in Washington state.
Kaiser Permanente screened dozens of people, looking for those who have no chronic health problems and are not currently sick. Researchers are not checking whether would-be volunteers already had a mild case of COVID-19 before deciding if they are eligible.
If some did, scientists will be able to tell by the number of antibodies in their pre-vaccination blood test and account for that, Jackson said. Participants will be paid $100 for each clinic visit in the study.

RELATED TOPICS:

DON'T MISS

Caitlin Clark and Iowa Draw Nearly 5 Million Viewers for Second-Round NCAA Win

DON'T MISS

Canadian School Boards Sue Snapchat, TikTok and Meta for Disrupting Students’ Education

DON'T MISS

California Law Enforcement Agencies Obstruct Transparency Efforts in Use-of-Force Cases

DON'T MISS

No Police Charges for Taylor Swift’s Dad Over Paparazzi Incident in Sydney

DON'T MISS

Biden Administration to Lend $1.5B to Restart Michigan Nuclear Power Plant, a First in the US

DON'T MISS

Tonight’s Biden Fundraiser With Obama and Clinton Already Nets a Record $25 Million

DON'T MISS

Former Sen. Joe Lieberman, Democrats’ VP Pick in 2000, Dead at 82

DON'T MISS

Trump Criticizes Judge and His Daughter After Gag Order in Hush-Money Case

DON'T MISS

Police Had About 90 Seconds to Stop Traffic Before Baltimore Bridge Fell. 6 Workers Are Feared Dead

DON'T MISS

NBC Has Cut Ties With Former RNC Head Ronna McDaniel After Employee Objections, Some on the Air

No data was found

Stock Market Today: Wall Street Rises to More Records to Close Out Its Latest Winning Month

2 hours ago

A Fresno County First: Kerman Council Passes Amended Gaza Cease-Fire Resolution

2 hours ago

UN Top Court Orders Israel to Open More Land Crossings for Aid into Gaza

2 hours ago

How Involved Is Southern California Consulting Firm in FUSD Executive Dealings?

2 hours ago

Biden’s Fundraiser with Obama and Clinton Nets a Record $25 Million, His Campaign Says

3 hours ago

Fresno Unified’s Self-Protection Racket Is Hurting Our Kids

3 hours ago

Rockin’ Out or Laughing, the Valley Has Its Pick of Weekend Events

4 hours ago

Ex-Correctional Officer at Women’s Prison in California Sentenced for Sexually Abusing Inmates

6 hours ago

Caitlin Clark and Iowa Draw Nearly 5 Million Viewers for Second-Round NCAA Win

6 hours ago

Canadian School Boards Sue Snapchat, TikTok and Meta for Disrupting Students’ Education

7 hours ago

Cronenworth’s Big Hit Helps Lift the Padres to a 6-4 Win Over Melvin’s Giants

SAN DIEGO — Jake Cronenworth’s two-run double highlighted a four-run seventh inning for the San Diego Padres, who beat the San Francis...

1 hour ago

1 hour ago

Cronenworth’s Big Hit Helps Lift the Padres to a 6-4 Win Over Melvin’s Giants

1 hour ago

Shohei Ohtani Reaches 3 Times in Home Debut as the Dodgers Rout the Cardinals 7-1

2 hours ago

Facebook News Tab Will Soon Be Unavailable as Meta Scales Back News and Political Content

2 hours ago

Stock Market Today: Wall Street Rises to More Records to Close Out Its Latest Winning Month

2 hours ago

A Fresno County First: Kerman Council Passes Amended Gaza Cease-Fire Resolution

2 hours ago

UN Top Court Orders Israel to Open More Land Crossings for Aid into Gaza

2 hours ago

How Involved Is Southern California Consulting Firm in FUSD Executive Dealings?

3 hours ago

Biden’s Fundraiser with Obama and Clinton Nets a Record $25 Million, His Campaign Says

MENU

CONNECT WITH US

Search

Send this to a friend